Navigate Up
Sign In
Cardio Program of Excellence in Glycosciences

Subroto Chatterjee, Ph.D.
Professor of Pediatrics
Division of Pediatric Cardiology
1383 Blalock Building
Johns Hopkins Hospital
600 N Wolfe Street
Baltimore, MD-21287
Office Phone: 410-614-2518
Lab Phone: 410-614-2524
Fax: 410-955-3247


CV.pdfSubroto Chatterjee CV.pdf​​​

Project 5

Glycosphingolipid/Glycosyltransferases and Cardiovascular disease

We will examine the critical roles of glycosphinglipids (GSLs) within the vascular cells in regulating the onset of atherosclerosis and hyper-cholesterolemia, which play an important role in the early stages leading to heart attack and heart disease. In this project, we identify an attractive therapeutic intervention that could ameliorate atherogenesis and cardiovascular disease (CVD) by targeting angiogenesis and cell proliferation regulated by glycosphingolipids. In collaboration with other projects and core laboratory facilities we will develop: new drugs aimed at ameliorating glycosphingolipid synthesis and atherogenesis accompanied by changes in the proteomics of glycosyltransferases. These studies may not only lay the foundation for the use of such agents to treat human CVD but also determine whether glycosphingolipid glycosyltransferases could serve as important biomarkers of the progression and severity of this disease.


In the News

Arsonists and Firefighters: The Perpetual Inflammatory Civil War for Survival
In this issue of Circulation, Chatterjee et al. describe an additive or alternative experimental approach to statin therapy. (Circulation)

John​s Hopkins Scientists Alter Fat Metabolism in Animals to Prevent Most Common Type of Heart Disease 
Working with mice and rabbits, Johns Hopkins scientists have found a way to block cholesterol production, transport and breakdown, successfully preventing the development of atherosclerosis, the main cause of heart attacks and strokes and the number one cause of death in humans. The National Heart, Lung, and Blood Institute supports this research. (NHLBI in the News)

Scientists at Johns Hopkins Come Closer to Eliminating Heart Disease
Scientists at Johns Hopkins University may be one step closer to eradicating debilitating heart diseases in humans, particularly those caused by excessive buildup of cholesterol. (The Daily Beast)


Chatterjee, S., Mishra, S., and Suzuki, S. "New vistas in lactosylceramide research". Adv. in Exptl. Med (2014): In press.

Mishra, S., and Chatterjee, S. "Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes." Glycobiology 24.6 (2014): 518-531.​

Chatterjee, S., Bedja, D., Mishra, S., Amuzie, C., Avolio, A., Kass, D.A., Berkowitz, D., Renehan, M. "Inhibition of Glycosphingolipid Synthesis Ameliorates Atherosclerosis and Arterial Stiffness in Apo E-/-Mice and Rabbits Fed a High Fat and Cholesterol Diet." Circulation 129.23 (2014): 2403-13.

Chatterjee, S. "Compositions and methods for treating cardiac hypertrophy." World Intellectual Property Organization. WO2013169936 A2. 14 Nov. 2013.

McNeal, C., Chatterjee, S., Hou, J., Worthy, L., Larner, C., MacFarlane, R., Alaupovic, P., Brocia, R. "Human HDL Containing a Novel ApoC-1 Isoform Induces Smooth Muscle Cell Apoptosis". Cardiovascular Res. 2013, 98: 83-93.

Chatterjee, S., et al. "Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model." PLOS ONE 8.5 (2013): e63726.

Chatterjee, S., Alsaeedi, N. "Lactosylceramide synthase as a therapeutic target to mitigate multiple human diseases in animal models". Adv. in Exp. Med. and Biol. 2012. 749; 153-169.

The CardioPEG has published more than 62 papers since 2011. See News and Publications​ for a complete list.​

Sphingolipid Signaling and Vascular Biology Laboratory News

Dr. Chatterjee's television interview airs Fall 2014 on Alhurra TV - الحرة
The Alhurra TV interview with Dr. S. Chatterjee on the topic " Glycoconjugates in atherosclerotic heart diseases and novel approaches for prevention" will be broadcast in the fall.

Summer 2014 Young Glycobiologists
This summer, our lab hosted four high school students –a new cadre of glycobiologists. This effort was a partnership with the Diversty and Academic Advancement Summer Institute (DAASI) and Biomedical Scholars Association (BSA).

(Pictured L-R): Devin Mobley (10th grade), Sarah Cai (12th grade), Aditya Sabu (11th grade), Sean Campbell (11th grade).

Sara Suzuki received a 2014-2015 Provost's Undergraduate Research Award.
Sara Suzuki has been awarded the PURA research award to conduct her project entitled, "Glycosyltransferases As Biomarkers of Proliferative Disorders".

Worldwide patent awarded to Dr. Subroto Chatterjee. In addition to filing one national phase patent and two new provisional patents, Dr. Chatterjee was awarded patent WO 2013169936 A2​ on the use of glycosyltransferase inhibitors to ameliorate ca​rdiac hypertrophy, entitled "Compositions and methods for treating cardiac hypertrophy".

Christine Amuzie awarded supplemental training grant by NIH/NHLBI for 2013-2015. The $100,000 award will support her predoctoral research, "An Exploration of the Role of lyso-Glycosphingolipids in Atherosclerosis".

Cardiologist Tang Nuo joined laboratory for sabbatical research from Shanghai University of Traditional Chinese Medicine. Dr. Tang will be separating and purifying the flavonoids and phytosterols used in traditional Chinese herbal medicine to treat atherosclerosis and cardiac hypertrophy for one year.

Puchong Thirawatananond received a 2013-2014 Provost's Undergraduate Research Award. Puchong received the prestigious PURA award at JHU to study the molecular changes in the murine renal system in response to a high fat and cholesterol diet.

Gangotri Jain joined the lab to complete her Int.M.Tech thesis research. Gangotri is currently enrolled in the joint degree program at Amity University, Uttar Pradesh in India. She will be performing a comparative analysis of nanocarriers versus free drug and biopolymer encapsulation as drug delivery mechanisms for six months.

Upcoming Seminars

CardioPEG Meeting
March 2015
Mt. Washington Conference Center

© Copyright 2012 PEG: Glycconjugates and Cardiovascular Disease
Site development by Modern Tymes, LLC
Cardio Program of Excellence
Sign In